Literature DB >> 29133562

Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.

Payal P Kakadiya1, Patricia Pecora Fulco2,3, Robert T Higginson3.   

Abstract

Entities:  

Keywords:  antiretrovirals; cobicistat; dabigatran; human immunodeficiency virus; ritonavir

Mesh：

Substances：

Year:  2018        PMID： 29133562      PMCID： PMC5786782          DOI： 10.1128/AAC.02275-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Authors:  Lori A Gordon; Parag Kumar; Kristina M Brooks; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jomy M George; Jay Lozier; Scott R Penzak; Colleen Hadigan
Journal:  Circulation       Date:  2016-12-06       Impact factor: 29.690

2.  Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation.

Authors:  Stefano Barco; Michiel Coppens; Erik-Jan van den Dool; Daan van de Kerkhof; An K Stroobants; Saskia Middeldorp
Journal:  Thromb Haemost       Date:  2014-07-03       Impact factor: 5.249

Review 3.  Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors:  Alice Tseng; Christine A Hughes; Janet Wu; Jason Seet; Elizabeth J Phillips
Journal:  Ann Pharmacother       Date:  2017-06-19       Impact factor: 3.154

4.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Authors:  Parag Kumar; Lori A Gordon; Kristina M Brooks; Jomy M George; Anela Kellogg; Maryellen McManus; Raul M Alfaro; Khanh Nghiem; Jay Lozier; Colleen Hadigan; Scott R Penzak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 5.  Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.

Authors:  Susan E Conway; Andrew Y Hwang; Charles D Ponte; John G Gums
Journal:  Pharmacotherapy       Date:  2017-02-03       Impact factor: 4.705

6.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

7.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

Authors:  Michael D Ezekowitz; Paul A Reilly; Gerhard Nehmiz; Timothy A Simmers; Rangadham Nagarakanti; Kambiz Parcham-Azad; K Erik Pedersen; Dominick A Lionetti; Joachim Stangier; Lars Wallentin
Journal:  Am J Cardiol       Date:  2007-08-17       Impact factor: 2.778

8.  Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

Authors:  Catia Marzolini; Sara Gibbons; Saye Khoo; David Back
Journal:  J Antimicrob Chemother       Date:  2016-03-05       Impact factor: 5.790

9.  A Pharmacist-Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV-Positive Patients.

Authors:  Ian R McNicholl; Monica Gandhi; C Bradley Hare; Meredith Greene; Edgar Pierluissi
Journal:  Pharmacotherapy       Date:  2017-11-30       Impact factor: 4.705

10.  Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.

Authors: 
Journal:  Lancet HIV       Date:  2017-05-10       Impact factor: 12.767
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.